Y. Ou

发表

Pharmacokinetic / Pharmacodynamic Predictors of Clinical Potency for 1 Hepatitis C Non-Nucleoside Polymerase and Protease Inhibitors 2 3

T. Lavé, M. Reddy, P. N. Morcos, 2012 .

Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator

Dongyang Liu, Y. Ou, S. Sahasranaman, 2021, CPT: pharmacometrics & systems pharmacology.

Physiologically‐based pharmacokinetic modelling to predict oprozomib CYP3A drug–drug interaction potential in patients with advanced malignancies

K. Papadopoulos, A. Tsimberidou, A. Mita, 2018, British journal of clinical pharmacology.

Comparison of pharmacokinetic interactions and physiologically based pharmacokinetic modeling of PCB 153 and PCB 126 in nonpregnant mice, lactating mice, and suckling pups.

Sun Ku Lee, Raymond S. H. Yang, Y. Ou, 2002, Toxicological sciences : an official journal of the Society of Toxicology.

Mechanism‐Based Pharmacokinetic–Pharmacodynamic Modeling During Discovery and Early Development

T. Lavé, M. Reddy, Y. Ou, 2011 .

Pharmacokinetics and Pharmacodynamics of CD4-Anchoring Bi-Functional Fusion Inhibitor in Monkeys

Y. C. Ou, Jun Zhang, Xingrong Liu, 2013, Pharmaceutical Research.

Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P‐gp and BCRP

W. Novotny, Y. Ou, S. Sahasranaman, 2020, British journal of clinical pharmacology.

Pharmacokinetic/Pharmacodynamic Predictors of Clinical Potency for Hepatitis C Virus Nonnucleoside Polymerase and Protease Inhibitors

T. Lavé, M. Reddy, P. N. Morcos, 2012, Antimicrobial Agents and Chemotherapy.

Albubnp, a Recombinant B-type Natriuretic Peptide and Human Serum Albumin Fusion Hormone, as a Long-Term Therapy of Congestive Heart Failure

Y. Ou, Wei Wang, Yanggu Shi, 2004, Pharmaceutical Research.

Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects

W. Novotny, S. Mu, Y. Ou, 2019, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study

Y. Ou, D. White, A. Spencer, 2017, Cancer Chemotherapy and Pharmacology.

In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor

Y. Ou, S. Sahasranaman, Lai Wang, 2021, Pharmacology research & perspectives.

Clinical pharmacology and PK/PD translation of the second-generation Bruton’s tyrosine kinase inhibitor, zanubrutinib

S. Opat, C. Tam, Y. Ou, 2021, Expert review of clinical pharmacology.

A Tumor Growth Inhibition Model Based on M‐Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single‐Agent Carfilzomib Use

S. Jagannath, D. Siegel, R. Vij, 2015, CPT: pharmacometrics & systems pharmacology.

Population Pharmacokinetics and Exposure–Response Relationship of Carfilzomib in Patients With Multiple Myeloma

M. Dimopoulos, S. Jagannath, R. Vij, 2017, Journal of clinical pharmacology.

Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study

R. Plummer, U. Vaishampayan, Y. Ou, 2017, Experimental Hematology & Oncology.

Physiologically Based Pharmacokinetic and Pharmacodynamic Modeling

Melvin E. Andersen, Brad Reisfeld, Raymond S. H. Yang, 2004 .

Stochastic simulation of hepatic preneoplastic foci development for four chlorobenzene congeners in a medium-term bioassay.

Raymond S. H. Yang, Russell S. Thomas, M. Andersen, 2003, Toxicological sciences : an official journal of the Society of Toxicology.

A two‐part, single‐arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies

Dengju Li, Y. Ou, Jun Zhu, 2022, British journal of haematology.

A phase 1, open-label, randomized drug–drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies

W. Novotny, S. Opat, Y. Ou, 2022, Leukemia & lymphoma.

Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma

W. Novotny, Y. Ou, A. Cohen, 2021, Leukemia & lymphoma.

A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers.

J. Zmuda, Y. Ou, G Mani Subramanian, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

No QTc Prolongation With Zanubrutinib: Results of Concentration‐QTc Analysis From a Thorough QT Study in Healthy Subjects

W. Novotny, S. Mu, B. Darpo, 2020, Clinical and translational science.

A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment

W. Novotny, R. Preston, T. Marbury, 2020, Leukemia & lymphoma.

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.

R. Moss, R. Rifkin, Y. Ou, 2016, Blood.

Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B‐Cell Malignancies

Y. Ou, S. Sahasranaman, Zhiyu Tang, 2020, Clinical and translational science.

Pharmacokinetics and Pharmacodynamics of CD4-Anchoring Bi-Functional Fusion Inhibitor in Monkeys

Jun Zhang, Xingrong Liu, Y. Ou, 2014, Pharmaceutical Research.

A physiologically based pharmacokinetic model for lactational transfer of PCB 153 with or without PCB 126 in mice

Melvin E. Andersen, Sun Ku Lee, Raymond S. H. Yang, 2007, Archives of Toxicology.

A Phase 1, Open‐Label, Fixed‐Sequence, Drug–Drug Interaction Study of Zanubrutinib with Rifabutin in Healthy Volunteers

Y. Ou, A. Cohen, S. Sahasranaman, 2023, Clinical pharmacology in drug development.

A A GENERAL REFERENCE ON PHYSIOLOGICALLY-BASED PHARMACOKINETIC / PHARMACODYNAMIC ( PBPK / PD ) MODELING

M. Andersen, B. Reisfeld, K. Liao, 2004 .